SyntekaBio, Inc. (KOSDAQ: 226330)

Market Cap	86.21B
Revenue (ttm)	124.38M
Net Income (ttm)	-7.42B
Shares Out	15.26M
EPS (ttm)	-483.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,409
Open	5,760.00
Previous Close	5,650.00
Day's Range	5,620.00 - 5,850.00
52-Week Range	5,400.00 - 19,960.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About SyntekaBio

SyntekaBio, Inc. operates as a genomic big data and artificial intelligence drug discovery company. It creates new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology, such as biomarkers for individual cancer drug screening and disease susceptibility by immunotyping, pharmacogenomic typing, and predicting multi-omics information-based drug adverse effects, etc. The company also developing new antigen prediction technology that can be used together with ...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Employees: 63
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226330

Financial Performance

In 2023, SyntekaBio's revenue was 123.41 million, a decrease of -49.42% compared to the previous year's 243.99 million. Losses were -11.40 billion, 152.9% more than in 2022.